Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab
 administered without dose escalation to patients with advanced B-cell chronic lymphocytic
 leukemia (B-CLL).
Inclusion Criteria:

 -  B-CLL that has failed fludarabine

 Exclusion Criteria:

 -  Performance status grade 3